1-4 of 4
Alisa Ruddell
Close
Sort by
Journal Articles

Tolerability of PTK787/ZK 222584 in a Phase II Study of Post-Transplant Maintenance Therapy in Patients with Multiple Myeloma Following High-Dose Chemotherapy and Autologous Stem Cell Transplant.

James C. Mosley, III, MD, Shachar Peles, M.D., Alisa Ruddell, B.A., Feng Gao, M.D., Ph.D., Camille Abboud, M.D., Amanda Cashen, M.D., Geoffrey Uy, M.D., Peter Westervelt, M.D., Ph.D., John F. DiPersio, M. D., Ph.D., Ravi Vij, M.D.
Journal: Blood
Blood (2007) 110 (11): 5109.
https://doi.org/10.1182/blood.V110.11.5109.5109
Published: 2007
Journal Articles

The KIT Tyrosine Kinase Inhibitor Midostaurine (PKC412) Exhibits a High Response Rate in Aggressive Systemic Mastocytosis (ASM): Interim Results of a Phase II Trial.

Jason Gotlib, Tracy I. George, Chris Corless, Andrea Linder, Alisa Ruddell, Cem Akin, Daniel J. DeAngelo, Ilana Kepten, Carlo Lanza, Heidrun Heinemann, Ophelia Yin, Neil Gallagher, Tim Graubert
Journal: Blood
Blood (2007) 110 (11): 3536.
https://doi.org/10.1182/blood.V110.11.3536.3536
Published: 2007
Journal Articles

The Activity and Toxicity of Dasatinib in Relapsed or Plateau-Phase Multiple Myeloma.

Tanya M. Wildes, MD, Alisa Ruddell, B.A., Feng Gao, M.D., Ph.D., Geoffrey Uy, M.D., Amanda Cashen, M.D., Camille Abboud, M.D., Peter Westervelt, M.D., Ph.D., John F. Dipersio, M.D., Ph.D., Ravi Vij, M.D.
Journal: Blood
Blood (2007) 110 (11): 1182.
https://doi.org/10.1182/blood.V110.11.1182.1182
Published: 2007
Journal Articles

Phase II Trial of the Tyrosine Kinase Inhibitor PKC412 in Advanced Systemic Mastocytosis: Preliminary Results.

Jason Gotlib, MD, MS, Tracy I. George, M.D., Andrea Linder, R.N., Alisa Ruddell, R.N., Sylvia Quesada, R.N., Cem Akin, M.D., Daniel J. DeAngelo, M.D.,Ph.D., Pamela Cohen, M.D., Timothy Graubert, M.D.
Journal: Blood
Blood (2006) 108 (11): 3609.
https://doi.org/10.1182/blood.V108.11.3609.3609
Published: 2006